{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-023423","form_type":"8-K","ticker":"ATOS","cik":"0001488039","company_name":"ATOSSA THERAPEUTICS, INC.","filed_at":"2023-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.062370+00:00","generated_at":"2026-06-11T10:48:41.912191+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Atossa Therapeutics Q2 2023 net loss $9.8M; clinical enrollment milestones; CFO appointed","bullets":["Cash at June 30, 2023: $99.4M, down from $110.9M at Dec 31, 2022.","Net loss Q2 2023: $9.83M vs $6.67M Q2 2022; operating expenses $7.79M up 18% YoY.","Impairment charge of $2.99M on investment in Dynamic Cell Therapeutics (DCT).","Phase 2 EVANGELINE PK cohort fully enrolled; Karisma-Endoxifen 70% enrolled; I-SPY 2 30% enrolled.","Appointed Greg Weaver as CFO; US patent granted for enterically encapsulated endoxifen."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-023423","json":"https://secwatch.observer/filing/0001437749-23-023423.json","markdown":"https://secwatch.observer/filing/0001437749-23-023423.md","text":"https://secwatch.observer/filing/0001437749-23-023423.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1488039/000143774923023423/0001437749-23-023423-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1488039/000143774923023423/atos20230804_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T10:48:41.912191+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"255f1a4a21962f074b5b33537b4af9f5dfc89fb5","claim":"ATOSSA THERAPEUTICS, INC. reported the quarter ended June 30, 2023 results: net income Net loss for the second quarter of 2023 was $9,830.","evidence_excerpt":"On August 14, 2023, Atossa Therapeutics, Inc. (the “Company”) issued a press release announcing the quarter ended June 30, 2023 financial results and a Company update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1488039/000143774923023423/0001437749-23-023423-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Net income","value":"Net loss for the second quarter of 2023 was $9,830"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}